The PRECiSE 2 trial of certolizumab pegol, a new PEGylated anti-TNF agent, in the treatment of Crohn’s disease: An interview with David A Schwartz, 13 June 2007

CONTEXT: Certolizumab pegol (CDP 870) is a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis. Certolizumab pegol is the first PEGylated biologic anti-TNF agent and has a high binding affinity for TNF. Dr. S...

Descripción completa

Detalles Bibliográficos
Autor principal: Schwartz, David A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727774/
https://www.ncbi.nlm.nih.gov/pubmed/19707435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727774/
https://www.ncbi.nlm.nih.gov/pubmed/19707435

Ejemplares similares